Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI – Get Free Report) crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.68 and traded as high as $0.7050. Brainstorm Cell Therapeutics shares last traded at $0.6801, with a volume of 1,817 shares traded.
Brainstorm Cell Therapeutics Stock Performance
The company has a market cap of $7.50 million, a PE ratio of -0.20 and a beta of 0.22. The firm has a fifty day simple moving average of $0.80 and a 200 day simple moving average of $0.68.
About Brainstorm Cell Therapeutics
BrainStorm Cell Therapeutics Inc (NASDAQ: BCLI) is a clinical‐stage biotechnology company focused on developing autologous cell therapies for the treatment of neurodegenerative diseases. The company’s proprietary platform leverages mesenchymal stem cells (MSCs) that are engineered to secrete neurotrophic and growth factors designed to support neuronal survival and function.
The company’s lead product candidate, NurOwn, is an autologous MSC therapy currently in advanced clinical development for amyotrophic lateral sclerosis (ALS).
See Also
- Five stocks we like better than Brainstorm Cell Therapeutics
- 3 Rare Earth Stocks That Win No Matter What China Does Next
- Amylyx Stock: Why the Full Pipeline Story Matters
- Palantir and Dell Build an AI OS for the Paranoid
- Workday Validates AI Flywheel: Stock Price Recovery Begins
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
